PURPOSE: The aim of the study was to asses quality of life and symptoms of obstructive sleep apnea syndrome (OSAS) patients after adhering to 6 months of continuous positive airway pressure (CPAP) treatment. METHODS: A group of 50 patients (41 men and 9 women) were diagnosed by polysomnography and treated with CPAP therapy for 6 months. Their symptoms and health-related quality of life were assessed by administering a validated and translated version of the sleep apnea quality of life index (SAQLI). Sleepiness was measured using the Epworth Sleepiness Scale (ESS) and through electronic monitoring of CPAP usage per night of sleep. RESULTS: Mean CPAP usage was 4.5 ± 0.5 h per night. Comparisons between quality of life indexes before and after CPAP treatment showed an improvement in the total SAQLI score (3.8 ± 0.9 vs. 5.8 ± 0.8 after CPAP, p < 0.01), in daily functioning (4.2 ± 1.4 vs. 6.0 ± 0.9, p < 0.01), social interactions (4.8 ± 1.3 vs.6.3 ± 0.7, p < 0.01), emotional functioning (4.4 ± 1.4 vs. 5.7 ± 1.0, p < 0.01), symptoms (1.6 ± 0.8 vs. 5.8 ± 1.2, p < 0.01), and in the ESS (13.7 ± 6.5 vs. 3.9 ± 3.8, p < 0.01). Regarding the patients' symptoms, improvement was noticed for "sleepiness while watching a spectacle" (96%), "reading" (95%), "carrying on a conversation" (95%), "driving" (92.9%), "restless sleep" (87.8%), and "urinating more than once per night" (84.8%). Smaller improvements were observed for the reported "dry mouth-throat upon awakening" (36.1%),"excessive fatigue" (54.5%), and "decreased energy" (55.3%). CONCLUSION: We conclude that OSAS patients who adhere to nighttime CPAP therapy show significant improvement of their quality of life, daytime sleepiness, and other symptoms after 6 months of treatment with CPAP.
PURPOSE: The aim of the study was to asses quality of life and symptoms of obstructive sleep apnea syndrome (OSAS) patients after adhering to 6 months of continuous positive airway pressure (CPAP) treatment. METHODS: A group of 50 patients (41 men and 9 women) were diagnosed by polysomnography and treated with CPAP therapy for 6 months. Their symptoms and health-related quality of life were assessed by administering a validated and translated version of the sleep apnea quality of life index (SAQLI). Sleepiness was measured using the Epworth Sleepiness Scale (ESS) and through electronic monitoring of CPAP usage per night of sleep. RESULTS: Mean CPAP usage was 4.5 ± 0.5 h per night. Comparisons between quality of life indexes before and after CPAP treatment showed an improvement in the total SAQLI score (3.8 ± 0.9 vs. 5.8 ± 0.8 after CPAP, p < 0.01), in daily functioning (4.2 ± 1.4 vs. 6.0 ± 0.9, p < 0.01), social interactions (4.8 ± 1.3 vs.6.3 ± 0.7, p < 0.01), emotional functioning (4.4 ± 1.4 vs. 5.7 ± 1.0, p < 0.01), symptoms (1.6 ± 0.8 vs. 5.8 ± 1.2, p < 0.01), and in the ESS (13.7 ± 6.5 vs. 3.9 ± 3.8, p < 0.01). Regarding the patients' symptoms, improvement was noticed for "sleepiness while watching a spectacle" (96%), "reading" (95%), "carrying on a conversation" (95%), "driving" (92.9%), "restless sleep" (87.8%), and "urinating more than once per night" (84.8%). Smaller improvements were observed for the reported "dry mouth-throat upon awakening" (36.1%),"excessive fatigue" (54.5%), and "decreased energy" (55.3%). CONCLUSION: We conclude that OSAS patients who adhere to nighttime CPAP therapy show significant improvement of their quality of life, daytime sleepiness, and other symptoms after 6 months of treatment with CPAP.
Authors: C Monasterio; S Vidal; J Duran; M Ferrer; C Carmona; F Barbé; M Mayos; N Gonzalez-Mangado; M Juncadella; A Navarro; R Barreira; F Capote; L R Mayoralas; G Peces-Barba; J Alonso; J M Montserrat Journal: Am J Respir Crit Care Med Date: 2001-09-15 Impact factor: 21.405
Authors: Maree Barnes; Danielle Houston; Christopher J Worsnop; Alister M Neill; Ivanka J Mykytyn; Amanda Kay; John Trinder; Nicholas A Saunders; R Douglas McEvoy; Robert J Pierce Journal: Am J Respir Crit Care Med Date: 2002-03-15 Impact factor: 21.405
Authors: Skai W Schwartz; Yuri Sebastião; Julie Rosas; Michelle R Iannacone; Philip R Foulis; W McDowell Anderson Journal: Sleep Breath Date: 2016-01-25 Impact factor: 2.816
Authors: Salma Batool-Anwar; James L Goodwin; Clete A Kushida; James A Walsh; Richard D Simon; Deborah A Nichols; Stuart F Quan Journal: J Sleep Res Date: 2016-05-30 Impact factor: 3.981
Authors: Harneet K Walia; Nicolas R Thompson; Irene Katzan; Nancy Foldvary-Schaefer; Douglas E Moul; Reena Mehra Journal: J Clin Sleep Med Date: 2017-11-15 Impact factor: 4.062
Authors: C Diamanti; E Manali; M Ginieri-Coccossis; K Vougas; K Cholidou; E Markozannes; P Bakakos; I Liappas; M Alchanatis Journal: Sleep Breath Date: 2013-02-06 Impact factor: 2.816
Authors: Jan Magnus Fredheim; Jan Rollheim; Rune Sandbu; Dag Hofsø; Torbjørn Omland; Jo Røislien; Jøran Hjelmesæth Journal: J Clin Sleep Med Date: 2013-05-15 Impact factor: 4.062
Authors: B Jurado-Gamez; W A Bardwell; L J Cordova-Pacheco; M García-Amores; N Feu-Collado; G Buela-Casal Journal: Sleep Breath Date: 2014-07-25 Impact factor: 2.816